Clinical trial
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
NCT00349830 · Stanford University, Other · Recruiting
Key facts
| NCT number | NCT00349830 |
|---|---|
| Title | Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy |
| Official title | Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy |
| Lead sponsor | Stanford University, Other |
| Status | Recruiting |
| Study type | Observational |
| Conditions | Carcinomas (Including Squamous Cell and Adenocarcinoma), Neoplasms |
| Intervention type | Procedure |
| Interventions | blood draw |
| Enrollment | 2,000 |
| Start date | Jan 1, 2002 |
| Primary completion | Jan 1, 2032 |
| Completion | Jan 1, 2032 |
| First posted | Jul 10, 2006 |
| Last update posted | Feb 10, 2026 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: